Pfizer/Sanofi’s Exubera May Need More Data In Asthma, COPD Patients
Executive Summary
Pfizer/Sanofi-Aventis' inhaled insulin powder Exubera may need additional information on pulmonary effects in patients with asthma and chronic obstructive pulmonary disease, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Sept. 8
You may also be interested in...
Pfizer Holding Its Breath On Exubera DTC Advertising To Focus On Education
Pfizer will begin direct-to-consumer advertising for its inhaled insulin therapy Exubera approximately one year after its approval, the company said at a June 10 briefing in Washington, D.C
Pfizer Holding Its Breath On Exubera DTC Advertising To Focus On Education
Pfizer will begin direct-to-consumer advertising for its inhaled insulin therapy Exubera approximately one year after its approval, the company said at a June 10 briefing in Washington, D.C
Exubera’s Post-Marketing Safety Program Is Industry Model – Pfizer’s Ryder
Pfizer's proposed post-marketing studies for the inhaled insulin therapy Exubera exemplify the type of risk management programs FDA should encourage industry to conduct, Pfizer Clinical R&D Senior VP Steven Ryder told an Institute of Medicine committee on Jan. 19